AI Energy (OTC:AEPCF) Stock, Quote.Headers.trade-ideas

AI Energy PCL is engaged in producing and distributing energy products, vegetable oil. The products provided by the company are biodiesel, refined glycerine and Palm oil product. The reportable segments of the company include, AI Energy Public Company Limited which is engaged in production and distribution of energy product (bio-diesel), vegetable oil and is also the key revenue generating segment for the company. Its another reportable segment is AI Ports and Terminals Company Limited which is involved in providing Ports service. The company operates principally in Thailand.

AI ENERGY PUB CO LTD by AI ENERGY PUB CO LTD.

AI Energy PCL

During the last three months, 6 analysts shared their evaluations of Sweetgreen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $43.83, a high estimate of $45.00, and a low estimate of $40.00. Marking an increase of 6.05%, the current average surpasses the previous average price target of $41.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1733947270_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Sweetgreen. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Charles</td>
<td>TD Cowen</td>
<td>Maintains</td>
<td>Buy</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Dennis Geiger</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Andrew Charles</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Brian Bittner</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Goldman Sachs</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Andrew Charles</td>
<td>TD Cowen</td>
<td>Maintains</td>
<td>Buy</td>
<td>$43.00</td>
<td>$43.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sweetgreen. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sweetgreen compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Sweetgreen's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Sweetgreen's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sweetgreen analyst ratings.</a>
<h2>Get to Know Sweetgreen Better</h2>
Sweetgreen Inc is a next-generation restaurant and lifestyle brand that serves healthy food at scale. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing.
<h3>Key Indicators: Sweetgreen's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Sweetgreen's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 13.04%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Sweetgreen's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -12.0%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -4.46%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Sweetgreen's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.42%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Sweetgreen's debt-to-equity ratio is below the industry average. With a ratio of 0.68, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Decoding 6 Analyst Evaluations For Sweetgreen

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Janux Therapeutics and provided 12-month price targets. The average target is $94.9, accompanied by a high estimate of $200.00 and a low estimate of $62.00. This upward trend is evident, with the current average reflecting a 5.89% increase from the previous average price target of $89.62.
<img src="https://www.benzinga.com/files/images/story/2024/1733947262_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Janux Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Josh Schimmer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$62.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Bradley Canino</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Jeffrey La Rosa</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$91.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Jeffrey La Rosa</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$79.00</td>
<td>-</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$63.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Josh Schimmer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>David Dai</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$69.00</td>
<td>-</td>
</tr>
<tr>
<td>Josh Schimmer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Janux Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Janux Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Janux Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Janux Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/JANX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Janux Therapeutics analyst ratings.</a>
<h2>Discovering Janux Therapeutics: A Closer Look</h2>
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
<h3>Unraveling the Financial Story of Janux Therapeutics</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Janux Therapeutics's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -82.56%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Janux Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -6391.57%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Janux Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -4.27%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -4.05%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Janux Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.04.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JANX

Navigating 10 Analyst Ratings For Janux Therapeutics

In the preceding three months, 4 analysts have released ratings for ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $197.5, along with a high estimate of $209.00 and a low estimate of $183.00. This current average has increased by 14.49% from the previous average price target of $172.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1733947242_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive ICU Medical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Toomey</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$209.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$198.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Michael Toomey</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$183.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ICU Medical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of ICU Medical compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of ICU Medical's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of ICU Medical's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ICUI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ICU Medical analyst ratings.</a>
<h2>Delving into ICU Medical's Background</h2>
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
<h3>Understanding the Numbers: ICU Medical's Finances</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, ICU Medical showcased positive performance, achieving a revenue growth rate of 6.47% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: ICU Medical's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -5.6%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): ICU Medical's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -1.61%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): ICU Medical's ROA excels beyond industry benchmarks, reaching -0.77%. This signifies efficient management of assets and strong financial health.
Debt Management: ICU Medical's debt-to-equity ratio is below the industry average. With a ratio of 0.81, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ICUI

A Glimpse Into The Expert Outlook On ICU Medical Through 4 Analysts

5 analysts have shared their evaluations of Zurn Elkay Water (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZWS#NYSE">ZWS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $38.0, along with a high estimate of $40.00 and a low estimate of $36.00. This current average reflects an increase of 6.74% from the previous average price target of $35.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1733947226_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Zurn Elkay Water. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Brett Linzey</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Bryan Blair</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$36.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Zurn Elkay Water. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Zurn Elkay Water compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Zurn Elkay Water's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Zurn Elkay Water's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ZWS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Zurn Elkay Water analyst ratings.</a>
<h2>Get to Know Zurn Elkay Water Better</h2>
Zurn Elkay Water Solutions Corp designs procure, manufactures, and markets a range of clean water solutions for drinking water, hygiene, and sustainable water management. The Zurn Elkay product portfolio includes professional-grade water control and safety, water distribution and drainage, drinking water, finish plumbing, hygienic, environmental and site works products for public and private spaces.
<h3>Key Indicators: Zurn Elkay Water's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Zurn Elkay Water showcased positive performance, achieving a revenue growth rate of 2.91% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Zurn Elkay Water's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 10.61%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Zurn Elkay Water's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.74%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Zurn Elkay Water's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.62%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Zurn Elkay Water's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.35.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Zurn Elkay Water: Insights From 5 Analyst Reviews

As the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38858599/artificial-intelligence-players-must-weigh-high-rewards-with-immense-risks-moodys">race to introduce</a> artificial intelligence features rages on, Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) unveiled a new prototype on Wednesday that could reshape the AI marketplace.
Google&#8217;s Mariner: &#8220;Project Mariner&#8221; is an AI prototype that <a href="https://deepmind.google/technologies/project-mariner/">operates</a> within users&#8217; browsers using Google&#8217;s Gemini 2.0 technology.
The experimental Chrome extension, not yet available to the public, &#8220;combines strong multimodal understanding and reasoning capabilities&#8221; to automate users&#8217; tasks. Google says that Mariner can &#8220;follow complex instructions and reason across websites.&#8221;
A promotional video showed the tool utilizing a Google Sheet of company names to scour the Internet for the companies&#8217; contact information. The tool shows the user its reasoning when searching the web, but it cannot operate in the background of a user&#8217;s browser.
Google says it is working with developers to speed up the tool to make the user experience smoother. It also emphasized that Mariner could be prone to making mistakes.
Users interested in accessing the tool can add their names to a &#8220;trusted tester&#8221; waitlist.
Why it Matters: Though Big Tech companies have invested hundreds of billions of dollars into AI, <a href="https://www.benzinga.com/news/events/24/11/42072183/will-ai-become-an-assistant-or-a-master-experts-beg-to-differ-at-benzinga-fintech-conference">it remains unclear</a> how useful the technology will end up being.
Some experts say that AI will not be able to find a foothold until it occupies a clear, &#8220;killer use case,&#8221; meaning it&#8217;s necessary that it proves the value of the technology as a whole. Past examples of killer applications include Microsoft&#8216;s Excel and Apple&#8216;s iTunes.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42443584/apple-strengthens-genai-with-ios-182-genmoji-image-playground-come-to-iphone">Apple Strengthens GenAI With iOS 18.2: Genmoji, Image Playground Come To iPhone</a></li>
</ul>
Image: Shutterstock

Equities

News

Tech

GOOG

GOOGL

Google Introduces AI Agent Prototype That Can Browse The Web

Ingersoll Rand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>) has outperformed the market over the past 5 years by 9.35% on an annualized basis producing an average annual return of 23.08%. Currently, Ingersoll Rand has a market capitalization of $41.41 billion. 
Buying $100 In IR: If an investor had bought $100 of IR stock 5 years ago, it would be worth $281.67 today based on a price of $102.75 for IR at the time of writing.
<h3>Ingersoll Rand's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733947216_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Ingersoll Rand Stock In The Last 5 Years

In the current market session, Ameriprise Finl Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) share price is at $548.15, after a 0.33% spike. Moreover, over the past month, the stock decreased by 1.62%, but in the past year, went up by 44.95%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1733947213_0.png" alt="Past Year Chart" />

<h3>A Look at Ameriprise Finl P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 43.96 in the Capital Markets industry, Ameriprise Finl Inc. has a lower P/E ratio of 20.88. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1733947213_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

P/E Ratio Insights for Ameriprise Finl

WIIM

ONON

On Holding shares are trading higher after Stifel maintained a Buy rating on the stock and raised its price target from $60 to $66.

Rumors

Legal

Watching Sable Offshore; Shares Move Higher, Traders Circulate Court Documents Suggesting Santa Barbara Withdrew Their Lawsuit

Bloom Energy shares are trading higher after the company announced a $125 million project financing partnership with HPS Investment Partners and Industrial Development Funding for 19 MW energy servers,

Goldman Sachs analyst Adam Hotchkiss initiated coverage on Similarweb Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/SMWB/analyst-ratings" rel="noreferrer noopener">price target of&nbsp;$16</a>.
Similarweb&#8217;s historical growth and profitability challenges have generally driven a growth-relative discount for the company&#8217;s shares to similar growth software companies, Hotchkiss noted. But recent go-to-market initiatives (i.e., Similarweb 3.0) are likely to drive sustainable mid-to-high teens growth with improving margins. 
This likely will lead to share price outperformance over the next 12 months, he adds.
Although 4.5 times represents a discount to software peers growing 10-20% annually (~6.6 times), Hotchkiss noted this as justified by Similarweb&#8217;s sub-scale profitability profile and higher-churn customer model, which creates greater volatility risk to numbers and growth. 
The analyst&#8217;s 4.5 times multiple is a premium to Similarweb&#8217;s three-year historical trading average, reflecting the company&#8217;s recent revenue acceleration, upside risk to numbers from data-as-a-service optionality, and improving profitability. Based on his current estimates, the price target implies ~29 times EV/FCF. 
However, he noted that minor variations in cash profitability could create swings in free cash flow valuation, given the company&#8217;s sub-scale profitability.
Hotchkiss projected fourth-quarter revenue of $65.4 million and adjusted earnings per share of 5 cents.
Price Action: Similarweb stock is up 6.86% at $13.02 at last check Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42420201/trumps-return-threatens-billions-in-us-chip-investment-from-taiwan-samsung" target="_blank" rel="noreferrer noopener">Trump&#8217;s Return Threatens Billions in US Chip Investment from Taiwan, Samsung</a></li>
</ul>
Image: Shutterstock edited via Canva

Price Target

Initiation

Movers

MSFT

SMWB

Goldman Sachs Initiates Similarweb Coverage, Product Upgrades Inspire Bullish Take

AquaBounty Technologies shares are trading lower after the company announced it will wind down its hatchery operations in Bay Fortune.

Goldman Sachs analyst Adam Hotchkiss downgraded E2open Parent Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NYSE">ETWO</a>) from Neutral to Sell and lowered the <a target="_blank" href="https://www.benzinga.com/quote/ETWO/analyst-ratings" rel="noreferrer noopener">price target from&nbsp;$3.5&nbsp;to&nbsp;$2.9</a>. The stock fell.
Despite year-to-date stock underperformance, Hotchkiss noted that the lack of visibility into an organic growth turnaround, execution risk as the company works to refine its organic sales engine further, and the company&#8217;s floating-rate leverage overhang will likely weigh on E2open Parent shares over the next 12 months.
As a business that has historically relied on acquired assets to support growth, E2open Parent&#8217;s elevated leverage in a high-interest rate environment is limiting the company&#8217;s ability to pay down debt to meet its leverage targets.
This cycle further limits the company&#8217;s ability to invest in growth initiatives (including acquisitions).
Also Read: <a target="_blank" href="https://www.benzinga.com/tech/24/12/42436800/stmicroelectronics-and-qualcomm-launch-new-iot-module-to-simplify-wireless-connectivity" rel="noreferrer noopener">STMicroelectronics and Qualcomm Launch New IoT Module to Simplify Wireless Connectivity</a>
In addition, with the company roughly doubling in size through acquired assets over the last 4 years, the amount of new ARR required to accelerate growth materially has subsequently doubled, driving an increased burden on cross-selling (particularly in an environment where new logo acquisition has slowed) to reaccelerate growth.
Absent further acquisitions and with further maturation of E2open Parent&#8217;s organic sales structure needed, Hotchkiss sought more clarity on the company&#8217;s ability to reaccelerate growth beyond low single digits over the near-to-medium term.
E2open Parent&#8217;s valuation is undemanding, but Hotchkiss noted that a rerating higher is unlikely absent an improvement in fundamentals, particularly given the multiple trough levels seen from peer-challenged growth software comps like Dropbox Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBX#NASDAQ">DBX</a>), RingCentral Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>), and SolarWinds Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWI#NYSE">SWI</a>).
While Hotchkiss agreed with management&#8217;s stated goals to pay down debt and focus on organic growth, he awaited evidence of progress toward these goals in a time of slowing organic growth relative to peers before considering turning more positive on E2open Parent stock.
With four consecutive quarters of declines in subscription revenue growth and lowered fiscal 2025 guidance, Hotchkiss noted it is prudent to be incrementally cautious around shares of E2open Parent despite the company trading near trough levels.
E2open Parents rapid conglomeration of assets and associated teams over the years has significantly increased the level of net new ARR needed to match historical growth levels on an organic basis, and meeting these levels of net new ARR at a time when larger transformation projects are increasingly being deferred (creating pressure on new logo growth) will likely remain a challenge for the company over at least the next 12-months.
Hotchkiss projected third-quarter revenue of $151.7 million and adjusted EPS of $0.04.
Price Action: ETWO stock is down 3.51% at $3.02 at last check Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42439924/match-group-under-pressure-to-deliver-strategy-for-tinders-struggles-and-hinge-growth-at-investor-meeting" target="_blank" rel="noreferrer noopener">Match Group Faces Investor Scrutiny Over Tinder Woes, Hinge Expansion Plans</a></li>
</ul>

Downgrades

ETWO

E2open Faces Organic Growth Challenges, Debt Overhang: Goldman Sachs Downgrades Stock

MYRG

MYR Group shares are trading higher after Stifel maintained a Buy rating on the stock and raised its price target from $153 to $172.

Alaska Air Group shares are trading higher after Morgan Stanley raised its price target on the stock from $70 to $90 while JP Morgan raised its price target from $58 to $85.

NFLX

Netflix shares are trading higher after JP Morgan maintained an Overweight rating on the stock and raised its price target from $850 to $1,010.

DBGI

Digital Brands Group shares are trading lower after the company announced a 1-for-50 reverse stock split.

LSCC

Lattice Semiconductor shares are trading higher after multiple firms raised their respective price targets on the stock,

Wells Fargo analyst Edward Kelly maintains Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) with a Equal-Weight and raises the price target from $95 to $105.

OLLI

Wells Fargo Maintains Equal-Weight on Ollie's Bargain Outlet, Raises Price Target to $105

Financial giants have made a conspicuous bullish move on Palo Alto Networks. Our analysis of options history for Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) revealed 15 unusual trades.
Delving into the details, we found 53% of traders were bullish, while 26% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $171,600, and 11 were calls, valued at $792,481.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $200.0 to $450.0 for Palo Alto Networks over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Palo Alto Networks's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Palo Alto Networks's whale activity within a strike price range from $200.0 to $450.0 in the last 30 days. 
<h3>Palo Alto Networks Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733946424_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PANW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$23.75</td>
<td>$22.7</td>
<td>$23.71</td>
<td>$400.00</td>
<td>$231.8K</td>
<td align="right">524</td>
<td align="right">100</td>
</tr>
<tr>
<td>PANW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$12.75</td>
<td>$12.4</td>
<td>$12.75</td>
<td>$450.00</td>
<td>$126.2K</td>
<td align="right">501</td>
<td align="right">100</td>
</tr>
<tr>
<td>PANW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$20.55</td>
<td>$19.55</td>
<td>$20.48</td>
<td>$420.00</td>
<td>$102.4K</td>
<td align="right">276</td>
<td align="right">58</td>
</tr>
<tr>
<td>PANW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$30.75</td>
<td>$30.4</td>
<td>$30.72</td>
<td>$400.00</td>
<td>$82.9K</td>
<td align="right">417</td>
<td align="right">84</td>
</tr>
<tr>
<td>PANW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$15.5</td>
<td>$14.85</td>
<td>$15.5</td>
<td>$400.00</td>
<td>$69.7K</td>
<td align="right">48</td>
<td align="right">49</td>
</tr>
</tbody>
</table>

<h3>About Palo Alto Networks</h3>
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.
<h3>Palo Alto Networks's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 955,126, the PANW's price is up by 2.15%, now at $398.13. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 69 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Palo Alto Networks with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

PANW

A Closer Look at Palo Alto Networks's Options Market Dynamics

AI Energy

Comments

AI Energy

AI Energy (AEPCF) Forecast

AI Energy (OTC:AEPCF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga